This site is intended only for all Healthcare Professionals residing in South Africa

Search

Menu

Close

Sign InLog Out Our medicinesTherapy areasExplore contentExplore contentEventsDownloadable materialsVideosLet’s connectLet's ConnectContact usPfizer medical information

Menu

Close

About ZAVICEFTAClinical EfficacySafety and tolerabilityThe ZAVICEFTA patientFull prescribing informationVideo Resources
Dosing
Prescribing information available at the bottom of the page

Normal renal function

Renal impairment

Tab Number 3

ZAVICEFTA® has consistent dosing across indications, with no dosage adjustments required in the elderly, patients with mild renal impairment (CrCL 50 - 79 mL/min) or those with hepatic impairment 1

*The dose of ZAVICEFTA® in patients with estimated CrCI ≤50 ml/min should be adjusted according to recommended doses. CrCI estimated using the Cockcroh-Gault formula
† To be used in combination with metronidazole when anaerobic pathogens are known or suspected to be contributing to the infectious process.
‡ To be used in combination with an antibacterial agent active against Gram-positive pathogens when these are known or suspected to be contributing to the infectious process.
§ The total duration shown may include intravenous ZAVICEFTA® followed by appropriate oral therapy. The time to switch from intravenous ZAVICEFTA® to oral treatment with another antibiotic depends on the clinical situation but is normally after about 5 days (the minimum duration of treatment with ZAVICEFTA® in clinical trials was 5 days).

Dosage adjustment is required for patients with renal impairment Recommended dose with renal impairment*
AbbreviationscIAI - complicated intra-abdominal infection; CrCI - creatinine clearance; cUTI - complicated urinary tract infection; HABP - hospital-acquired bacterial pneumonia; VABP - ventilator-associated bacterial pneumonia.
ReferencesZavicefta® South African Approved Professional Information date of publication (21 September 2021)Carmeli Yet al. Lancet Infect Dis 2016;16:661-73;Mazuski JE, et al. Clin Infect Dis 2016;62:1380-9;Wagenlehner FM, et al. Lancet Infect Dis 2016;63:754-62;Torres Aet al. Lancet Infect Dis 2018;18:285-95;Mazuski JEet al. Surg Infect (Marchmnt) 2017;18:1-76;
View ZAVICEFTA® Prescribing information Loading
*ZAVICEFTA® South African Approved Professional Information date of publication (21 September 2021).PP-ZVA-ZAF-0029
Clinical Information Support & Services See safety outcomes Loading Learn more about ZAVICEFTA® patient Loading

Copyright ©2023 Pfizer South Africa All rights reserved.

  • The information contained herein is provided for educational purposes only and is not intended to constitute medical advice or replace discussions with a Healthcare Professional. All decisions regarding patient care must be made with a Healthcare Professional, considering the unique characteristics of the patient.
  • While every effort is made to update the information regularly and to offer the most current, correct and clearly expressed information possible, Pfizer cannot be held responsible for any inaccuracy, errors, omissions or misinterpretations.
  • Pfizer, its officers and/or its employees do not accept or take any responsibility whatsoever for any loss, whether direct, indirect or consequential, which may arise from reliance on information contained on these pages and actions resulting therefrom. Any liability that would or could arise as a result of the contents of these pages is hereby excluded to the fullest extent allowed by law.
  • No warranty is given that any files, downloads or applications available via this web site are free of viruses which have the ability to corrupt your system.
  • Any and all information is subject to change without notice.
  • The information provided in this site is intended only for appropriate Healthcare Professionals residing in South Africa.

 

PfizerPro AccountPfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign inRegisterAccountSign Out

This site is intended only for all Healthcare Professionals residing in South Africa. If you are a member of the public wishing to access information on a specific medicine, please visit www.pfizer.co.za.

 

This website is brought to you by Pfizer South Africa 

Pfizer Laboratories (Pty) Ltd. Company Reg. No. 1954/000781/07. Building 2, 1st Floor, Maxwell Office Park, Magwa Crescent, Waterfall City, Midrand, Johannesburg, South Africa. Tel. No: 0860 PFIZER (734937).

 

Copyright © 2023. Pfizer Laboratories (Pty) Ltd. All rights reserved

PP-UNP-ZAF-0188
For South Africa Healthcare Professionals *


These pages are not intended for patients or for members of the general public. The healthcare professional webpages contain promotional content.

I confirm that I am a healthcare professional residing in South Africa. If you select 'No', you will be redirected to Pfizer.co.za where you will be able to access reference information on Pfizer's prescription medicines.
 

Yes No
You are now leaving the PfizerPro South Africa website
You are leaving the South Africa HCP Portal website and being directed to a new website

This website is not controlled by South Africa HCP portal or subject to our privacy policy.

Thank you for visiting our site. We hope your visit was informative and enjoyable